- Home
- AGMH vs CLRB Comparison
AGMH vs CLRB Comparison
Compare AGMH & CLRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGMH
- CLRB
- Stock Information
- Founded
- AGMH 2015
- CLRB 2002
- Country
- AGMH Hong Kong
- CLRB United States
- Employees
- AGMH N/A
- CLRB N/A
- Industry
- AGMH EDP Services
- CLRB Biotechnology: Pharmaceutical Preparations
- Sector
- AGMH Technology
- CLRB Health Care
- Exchange
- AGMH Nasdaq
- CLRB Nasdaq
- Market Cap
- AGMH 17.1M
- CLRB 17.5M
- IPO Year
- AGMH 2018
- CLRB N/A
- Fundamental
- Price
- AGMH $6.87
- CLRB $5.02
- Analyst Decision
- AGMH
- CLRB Hold
- Analyst Count
- AGMH 0
- CLRB 2
- Target Price
- AGMH N/A
- CLRB N/A
- AVG Volume (30 Days)
- AGMH 12.0M
- CLRB 83.9K
- Earning Date
- AGMH 11-18-2025
- CLRB 11-17-2025
- Dividend Yield
- AGMH N/A
- CLRB N/A
- EPS Growth
- AGMH N/A
- CLRB N/A
- EPS
- AGMH 6.43
- CLRB N/A
- Revenue
- AGMH $32,044,575.00
- CLRB N/A
- Revenue This Year
- AGMH N/A
- CLRB N/A
- Revenue Next Year
- AGMH N/A
- CLRB N/A
- P/E Ratio
- AGMH $1.11
- CLRB N/A
- Revenue Growth
- AGMH N/A
- CLRB N/A
- 52 Week Low
- AGMH $1.09
- CLRB $4.11
- 52 Week High
- AGMH $107.50
- CLRB $66.60
- Technical
- Relative Strength Index (RSI)
- AGMH 56.76
- CLRB 43.54
- Support Level
- AGMH $7.59
- CLRB $5.31
- Resistance Level
- AGMH $9.49
- CLRB $6.52
- Average True Range (ATR)
- AGMH 1.98
- CLRB 0.41
- MACD
- AGMH -0.07
- CLRB -0.01
- Stochastic Oscillator
- AGMH 28.82
- CLRB 3.18
About AGMH AGM Group Holdings Inc.
AGM Group Holdings Inc is an integrated technology company. The company focuses on blockchain-oriented ASIC chip design, high-end crypto miner production, and fintech technology software services. The company generates maximum revenue from the sale of cryptocurrency mining machines and standardized computing equipment.
About CLRB Cellectar Biosciences Inc.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.